CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
MAUREEN M. GOODENOW, Ph.D.
Stephany W. Holloway University Professor
University of Florida College of Medicine
Gainesville, Florida 32610
PH 352/273-8165 FAX 352/273-8284
e-mail: goodenow@ufl.edu
EDUCATION
B.S., Biology
Fordham University, Bronx, New York
Ph.D., Genetics
Albert Einstein College of Medicine, Bronx, New York
______________________________________________________________________________________________
ACADEMIC APPOINTMENTS
Predoctoral Student, Department of Genetics, Albert Einstein College of Medicine
Postdoctoral Fellow, Laboratory of Molecular Genetics & Oncology
Memorial Sloan-Kettering Cancer Center, New York, NY
Visiting Scientist, Laboratory of Molecular Biology & Immunology of Retroviruses
Pasteur Institute, Paris, France
Assistant Professor, Department of Pathology, University of Florida College of Medicine [UFCOM]
Assistant Professor, Department of Pediatrics, Division of Immunology, UFCOM
Associate Professor [with tenure], Department of Pathology, Immunology & Laboratory Medicine
and Department of Pediatrics, Division of Immunology & Infectious Disease, UFCOM
Professor, Department of Pathology, Immunology, & Laboratory Medicine
and Department of Pediatrics, Division of Immunology & Infectious Disease, UFCOM
Senior Member, University of Florida Shands Cancer Center
Associate Director for Research, Department of Pathology, Immunology & Laboratory Medicine
Director for Research, Department of Pathology, Immunology & Laboratory Medicine
Director, Center for Research in Pediatric Immune Deficiency
Director, Florida Center for AIDS Research [FL CFAR]
1977-1983
1983-1987
1987-1988
1988-1994
1990-1994
1994-1999
1999 - present
2001 - present
2002 - 2005
2005 – 2007
2004-present
2007 - present
HONORS AND AWARDS
National Cancer Institute Predoctoral Trainee
Postdoctoral Fellowships
Damon Runyon-Walter Winchell Cancer Fund
American Cancer Society (declined)
NIH National Research Service Award
INSERM Poste Orange, Institute National de la Sante et de la Recherche Medicale, France
New Faculty Award, Division of Sponsored Research University of Florida
Young Investigator Award, Interdisciplinary Center for Biotechnology, University of Florida
Research Development Award, Division of Sponsored Research, University of Florida
Shannon Award, National Institute of Child Health and Human Development
Frontline Leadership Training and Management Series
Fourth Annual Workshop on Academic Management
University of Florida Research Bank Award
University of Florida Research Award
UF Research Foundation Professor
Executive Leadership for Academic Medicine [ELAM] Fellow
Stephany W. Holloway University Chair for AIDS Research [$4 M superchair]
UF College of Medicine Basic Research Award
1977 - 1982
1983 - 1985
1985 - 1986
1987 - 1988
1988
1988
1989
1994
1996
1996
1997
1999 - 2002
2002 - 2004
2004 - 2005
2004 – present
2011
CONSULTANT
Montgomery & Larmoyeux, Miami, FL. Attorneys for the plaintiff in a case involving transmission of HIV-11993-1994
Smith Kline Beecham, PA. Evaluation of compounds for antiviral activity
1996
Roche Molecular Systems, Alameda, CA
1997 - 1999
District Attorney, Bronx, NY Analysis of transmission of HIV-1 in a criminal case
1998
1
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
City University of New York, Office of the Chancellor, Advisor for reorganization of the Doctoral Programs
in Science [Biology, Biochemistry, Physics, and Chemistry]
2006
City University of New York, Office of the Vice-Chancellor for Research, Interim review of Doctoral Programs
in Science [Biology, Biochemistry, Physics, and Chemistry]
2011
COMMITTEES, PROGRAMS, and CENTERS
Community
Community Advisory Board for Pediatric Clinical Trials for HIV-1 Disease
National and International
NIH DRG Immunology, Virology, and Pathology Review Group
NIMH AIDS Research Review Committee, Psychobiological, Biological, and
Neurosciences Subcommittee, Special Reviewer
Elizabeth Glaser Pediatric AIDS Foundation, Children's Research Fund Advisory Committee
NIH NIAID Special Review Committee and Source Selection Group for RFP
"Genetic Sequence Variability of HIV-1 and Related Lentiviruses"
NIH DRG AIDS and Related Research C (AARC), Special Reviewer
NIH NIAID Special Review Committee for RFA "Multicenter AIDS Cohort Study Pathogenesis Lab"
NIH NIAID Special Review Committee for RFA "Mechanisms of AIDS Pathogenesis"
NIH DRG AIDS and Related Research C (AARC), Special Reviewer
NIH DRG AIDS and Related Research A (ARRA), Special Reviewer
NIH DRG AIDS and Related Research C (ARRC), Special Reviewer
NIH NIAID Special Review Committee for RFA Acute and Early HIV-1 Infection
NIH NIAID Special Review Committee for renewal of Multicenter AIDS Cohort Studies
NIH NIAID Special Review Committee for AIDS Vaccine Trial Centers [declined]
NIH NIAID Special Review Committee for RFA "Multicenter AIDS Cohort Study Pathogenesis Lab"
Pediatric AIDS Clinical Trial Group [PACTG]
Virology Committee, Vice Chair
Virology Committee, Chair
Laboratory Steering Committee
Research Prioritization Subcommittee
PACTG and Adolescent Trials Network Protocol Virologist
NIH ORS AIDS and Related Research (ARR6), Member
NIH Office of the Director, Office of AIDS Research,
Etiology and Pathogenesis Planning Committee
Association of Academic Health Centers, Committee for Vice Presidents for Research
Special Advisory Committee for Graduate Programs to the Chancellor, City University of New York
NIH CSR AIDS Molecular and Cell Biology Study Section, Member
NIH, NIAID, AIDS Research Advisory Committee (ARAC)
NIH NIAID Special Emphasis Panel RFA-AI-09-018:
Dissecting the Early HIV Immune Response: A Systems Biology Approach
International AIDS Society, Working Group to develop strategy for a cure for HIV
University [Department, Centers, COM, Health Center]
Coordinator, Graduate Program in Immunology and Molecular Pathology
Graduate Coordinators Committee, College of Medicine
Training Grant in Cancer Biology
Steering Committee
Associate Director
Co-Director & Co-PI
College of Medicine Deans Committee, Basic Science Reorganization
College of Medicine Dean’s Faculty Research Advisory Board
College of Medicine Faculty Council Secretary
College of Medicine Dean’s Search Committee for Director of Cancer Center
Senior Member, UF Shands Cancer Center
Co-director, Division of Experimental Pathology, Department of Pathology
Center for Studies of Women’s Health Board of Directors
College of Medicine Dean’s Compensation Committee
College of Medicine Incentive Fund Review Panel
2
1997-2006
1989 - 1993
1990
1992 - present
1993
1994
1994
1995
1995
1996
1996
1997
1998
1999
1999
2001 - 2004
2004 - 2006
2004 - 2006
2004 - 2006
2002 - 2007
2000 - 2004
2003 - present
2005 - present
2006
2006 - 2010
2008 – 2012
2010
2010-present
1991 - 1992
1991 - 1992
1988 - present
1996 - 2000
2000 - present
1995 - 1996
1997
1996 - 1999
1998
2001 - present
1998 - 2000
1998 - 2000
1999
2000 - 2002
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
Department of Pathology Compensation Committee
2000 – 2006
Department of Pediatrics, Chair of Search Committee for Division of Immunology & Infectious Diseases
2001
Director, Center of Excellence for Research in Pediatric Immune Deficiency
2003 - present
Health Science Center, Vice President, McKnight Brain Institute Leadership Transition
2003
Health Science Center, Vice President, Special Project: Role of Centers and Institutes in
Interdisciplinary Research
2003-2006
Chair, Search Committee, UFSCC and Department of Pathology, Tumor Immunology
2006
Chair, Thomas Maren Endowment for Junior Investigators
2007 - present
Member, Search Committee for Chair of Molecular Genetics & Microbiology
2008 – 2010
Medical School Admissions Committee, College of Medicine [2008-2011]
declined
Member, Academic Personnel Board, University of Florida [2008-2011]
declined
Member, Department of Pathology Task Force to develop postdoctoral mentoring policies
2010-2011
Member, Department of Pathology Search Committee for Immunology position
2010-2011
Chair, Department of Pathology Search Committee for Research Assistant Professor
2011
Program Leader, Molecular Oncology Program, UFSCC
2010-present
EDITOR Journal of Leukocyte Biology
SCIENTIFIC EDITORIAL BOARD Antimicrobial Agents and Chemotherapy, AIDS (3 year term starting 1/1/11)
REVIEWER Journal of Virology, Journal of Infectious Diseases, Oncogene, Virology, AIDS, Clinical Immunology and
Immunopathology, AIDS Research and Human Retroviruses, Journal of Neuroimmunology, Laboratory Investigation,
PUBLICATIONS (peer-reviewed)
Plata, F., M.M. Goodenow and F. Lilly. Studies of cloned Friend erythroleukemia tumor cells. Modulation of the
tumor-specific cytolytic T lymphocyte response by infectious Friend virus production in vitro. J. Exp. Med. 151:726742, 1980.
Goodenow, M.M. and F. Lilly. Expression of differentiation and murine leukemia virus antigens on cells of primary
tumors and cell lines derived from chemically induced lymphomas of RF/J mice. Proc.Natl.Acad.Sci.USA 81:76127616, 1984.
Shih, C.-K., M. Linial, M.M. Goodenow and W.S. Hayward. Nucleotide sequence 5' of the chicken c-myc coding
region: localization of a non-coding exon that is absent from myc transcripts in most ALV-induced lymphomas. Proc.
Natl. Acad. Sci. USA 81:4697-4701, 1984.
Chinsky, J., M.M. Goodenow, M. Jackson, F. Lilly, L. Leinwand and G. Childs. Comparison of endogenous murine
leukemia virus proviral organization and RNA expression in RF and AKR mice. J. Virol. 53:94-99, 1985.
Goodenow, M.M., K. Kessler, L. Leinwand and F. Lilly. Absence of trisomy 15 in chemically induced murine T-cell
lymphomas. Cancer Genet. Cytogenet. 19:205-211, 1986.
Goodenow, M.M. and W.S. Hayward. 5' long terminal repeats of myc- associated proviruses appear structurally intact
but are functionally impaired in tumors induced by avian leukosis viruses. J. Virol. 61:2489-2498, 1987.
Goodenow, M., T. Huet, W. Saurin, S. Kwok, J. Sninsky, and S. Wain-Hobson. HIV-1 isolates are rapidly evolving
quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J. Acquir. Immune Defic. Syndr.
2:344-352, 1989.
Plata, F., F. Garcia-Pons, A. Ryter, F. Lebargie, M.M. Goodenow, M.H. Quan Dat, B. Autran, and C. Mayaud. HIV-1
infection of lung alveolar fibroblasts and macrophages in humans. AIDS Res. and Human Retroviruses 6:979-986,
1990.
Farmerie, W.G., M.M. Goodenow, and B.M. Dunn. Cloning, expression and kinetic characterization of the feline
immunodeficiency virus proteinase. Adv Exp Med Biol. 306:511-513, 1991.
Grimes, H.L., B.E. Szente, and M.M. Goodenow. C-ski cDNAs are encoded by eight exons, six of which are closely
linked in the chicken genome. Nuc. Acids Res. 20:151-156, 1992.
Bottazzi, M.E., M.M. Goodenow, M.G. Moscovici, and C. Moscovici. BM2L is a spontaneous leukemogenic variant of
a non-leukemogenic v-myb transformed myeloid cell line. Oncogene 8:731-736, 1993.
Lamers, S.L., J.W. Sleasman, K.A. Barrie, S.M. Pomeroy, D.J. Barrett, and M.M. Goodenow. Independent variation
and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type
1 in vivo. J. Virol. 67:3951-3960, 1993.
3
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
Grimes, H.L., M.R. Ambrose, and M.M. Goodenow. C-ski transcripts with and without exon 2 are expressed in
skeletal muscle and throughout chick embryogenesis. Oncogene 8:2863-2868, 1993.
Lamers, S.L., J.W. Sleasman, K.A. Barrie, S.M. Pomeroy, D.J. Barrett, and M.M. Goodenow. Persistence of multiple
maternal HIV-1 genotypes in infants infected by perinatal transmission. J. Clin. Invest. 93:380-390, 1994.
Sleasman, J.W., T.O. Harville, G.B. White, J. George, D.J. Barrett, and M.M. Goodenow. Arrested rearrangement of
T cell receptor V-beta genes in thymocytes from children with X-linked severe combined immunodeficiency disease. J.
Immunol. 153:442-448, 1994.
Bhatt, D., L. Zhang, A. Gustchina, L. Reshetnikova, A. Wlodawer, W. Farmerie, M.M. Goodenow and B. M. Dunn.
Structure and enzymology of FIV and HIV proteases: relation to the development of AIDS drug resistance. Protein
Science 4, 2:91-98, 1995.
Wlodawer, A., A. Gustchina, L. Reshetnikova, J. Lubkowski, A. Zdanov, K.Y. Hui, E.L. Angleton, W.G. Farmerie, M.M.
Goodenow, D. Bhatt, and B.M. Dunn. Crystal structure of an inhibitor complex of the protease from feline
immunodeficiency virus. Nature Struct. Biol. 2:480-488, 1995.
Ambrose, M.R., M.E. Bottazzi, and M.M. Goodenow. Expression of the c-ski proto-oncogene during cell cycle arrest
and myogenic differentiation. DNA Cell Bio. 14:701-707, 1995.
Aleixo, L., M.M. Goodenow, and J.W. Sleasman. Highly enriched populations of T cell depleted monocytes verified by
molecular analysis. Clin. Diagnostic Lab. Immunol. 2:733-739, 1995.
Barrie, K.A., E. Perez, S.L. Lamers, J.W. Sleasman, B.M. Dunn, and M.M. Goodenow. Natural variation in HIV-1
protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: amino acid substitutions in the
absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology
219:407-416, 1996.
Lamers, S.L., J.W. Sleasman, and M.M. Goodenow. A model for alignment of V1 and V2 hypervariable domains of
Env gp120 in human immunodeficiency virus type 1 (HIV-1): Positions of charged amino acids are conserved. AIDS
Res. Human Retroviruses 12:1169-1178, 1996.
Sleasman, J.W., L.F. Aleixo, A. Morrow, S. Skoda-Smith, and M.M. Goodenow. CD4+ memory T cells are the
predominant population of HIV-1 infected lymphocytes in neonates and children. AIDS 10:1477-1484, 1996.
Aleixo, L., M.M. Goodenow, and J.W. Sleasman. Zidovudine administered to HIV-1 infected women and their
neonates reduces pediatric infection independent of an effect on levels of maternal virus. J.Pediatr.130:906-914, 1997.
Sleasman, J.W., B.H.Leon, L.F. Aleixo, M. Rojas, and M.M. Goodenow. Immunomagnetic selection of purified
monocyte and lymphocyte populations from peripheral blood mononuclear cells following cryopreservation. Clin.
Diagnostic Lab. Immunol. 4:653-658, 1997.
Massengill, S.M., M.M. Goodenow, and J.W. Sleasman. SLE nephritis is associated with an oligoclonal expansion of
intrarenal T cells. Am J Kidney Dis. 31:418-426, 1998.
Krebs, F.C., D. Mehrens, S. Pomeroy, M.M. Goodenow, and B. Wigdahl. Human immunodeficiency virus type 1 long
terminal repeat quasispecies differ in basal transcription and nuclear factor requirement in human glial cells and
lymphocytes. J. Biomed. Sci. 5:31-44, 1998.
Bloom G., E. Perez, S. Parikh, J. Kay, J. Mills, M. Goodenow, B.M. Dunn. A comparison of gag-pol precursor
cleavage in naturally arising HIV variants. Adv. Exp. Med. Biol. 436:53-57, 1998.
Tuttle, D.L., J.K. Harrison, C.B. Anders, J.W. Sleasman, and M.M. Goodenow. Expression of CCR5 increases during
monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency
virus type 1. J. Virol. 72:4962-4969, 1998.
Skinner, L.T., S.L. Lamers, M.M. Goodenow, and M. Katzman. Analysis of a large collection of natural HIV-1 integrase
sequences, including those from long-term non-progressors. J.A.I.D.S. Human Retovirol. 19:99-110, 1998.
Zeichner, S.L., P. Palumbo, Y.Feng, X. Xiao, D. Gee, J. Sleasman, M.M. Goodenow, R. Biggar, and D. Dimitrov.
Rapid telomere shortening in children. Blood 93:1-8, 1999.
Sleasman, J.W., R.P. Nelson, M.M. Goodenow, D. Wilfert, A. Hutson, M. Baseler, J. Zuckerman, P.A. Pizzo, and B.U.
Mueller. Immunoreconstitution following ritonavir therapy in HIV-infected children involves multiple lymphocyte
lineages. J. Peds. 134:597-606, 1999.
Burkhardt, B., D.Kephart, C. Coberley, J. Sleasman, and M. Goodenow. Postmortem isolation and analysis of human
genomic DNA and HIV-infected tissues: a molecular diagnostics application. Promega Notes 71:30-31, 1999.
4
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
Ping, L-H., J.Nelson, I.F.Hoffman, J.Schock, S.L.Lamers, M.Goodman, P.Vernazza, P.Kazembe, M.Maida, D.Zimba,
M.M. Goodenow, S.A.Fiscus, M.S.Cohen, and R Swanstrom. Characterization of V3 sequence heterogeneity in
subtype C HIV-1 isolates from Malawi: underrepresentation of X4 variants. J.Virol.73:6271-6281, 1999.
Acquino de Jesus, M.J., C. Anders, G. Miller, J.W. Sleasman, M.M. Goodenow, and W.A. Andiman. Genetically and
epidemiologically related non-syncytium-inducing isolates of HIV-1 display heterogeneous growth patterns in
macrophages. J.Med.Virol.61: 171-180, 2000.
Kouba, J.K., B.R. Burkhardt, I.M. Alavarez, M.M. Goodenow, and W.C. Buhi. Oviductal plasminogen activator
inhibitor-1 [PAI-1]: mRNA, protein, and hormonal regulation during the estrous cycle and early pregnancy in the pig.
Mol. Reprod. Develop. 56:378-386, 2000.
Lathey, J.L., D. Brambilla, M.M. Goodenow, M. Nokta, S. Rasheed, E.B. Siwak, J.W. Bremer, D.D. Huang, Y. Yi, P.S.
Reichelderfer, and R.G. Collman for the Macrophage Tropic Viral Kinetic Team [MTVK], PACTG, NIAID. Co-receptor
usage was more predictive than NSI/SI phenotype for HIV replication in macrophages: Is NSI/SI phenotyping
sufficient? J. Leukoc. Biol. 68:324-330, 2000.
Kou, Z., J. Puhr, M. Rojas, W.T.McCormack, M.M.Goodenow, and J.W. Sleasman. T cell receptor Vβ repertoire CDR3
length diversity differs within CD45RA and CD45RO T cell subsets in healthy and HIV-infected children. Clin. Diag.
Lab. Immunol. 7:953-959, 2000.
Briggs, D.R., D.L.Tuttle, J.W. Sleasman, and M.M. Goodenow. Envelope V3 amino acid sequence predicts HIV-1
phemotype [coreceptor usage and tropism for macrophages]. AIDS 14:2937-2940, 2000.
David, S.A., M.S. Smith, G.J. Lopez, I. Adany, S. Mukherjee, S. Buch, M.M. Goodenow, and O. Narayan. Selective
transmission of R5-tropic HIV type 1 from dendritic cells to resting CD4+ T cells. AIDS Res Hum Retroviruses. 17:5968, 2001.
Perez, E.E., S.L. Rose, B. Peyser, S.L. Lamers, B. Burkhardt, B.M. Dunn, A.D. Hutson, J.W. Sleasman, and M.M.
Goodenow. HIV-1 protease genotype predicts immune and viral response to combination therapy with protease
inhibitors [PI] in PI-naïve patients. J. Inf. Dis. 183:579-588, 2001.
Mergia, A., S. Chari, D.L.Kolson, M.M. Goodenow, and T. Ciccarone. The efficiency of simian foamy virus vector type1 (SFV-1) in non-dividing cells and in human PBLs. Virology 280:243-52, 2001.
Gaffari,G., D.J. Passalacqua, B.S. Bender, D.J. Briggs, M.M. Goodenow, and J.W. Sleasman. Human lymphocyte
proliferation responses following primary immunization using rabies vaccine as a neoantigen. Clin. Diag. Laboratory
Immunol. 8:880-883, 2001.
Goodenow, M.M., G. Bloom, S.L. Rose, S.M. Pomeroy, P.O. O’Brien, E.E. Perez, J.W. Sleasman, and B.M. Dunn.
Naturally occurring amino acid polymorphisms in human immunodeficiency virus type 1 [HIV-1] Gag p7NC and the Ccleavage site impact Gag-Pol processing by HIV-1 protease. Virology 292:137-149, 2002.
Tuttle, D.L., C.B. Anders, M.J. Acquino-de Jesus, P.P. Poole, S.L. Lamers, D.R. Briggs, S.M. Pomeroy, L. Alexander,
K.W.C.Peden, W.A. Andiman, J.W. Sleasman, and M.M. Goodenow. Increased replication by nonsyncytium-inducing
HIV-1 isolates in monocyte-derived macrophages is linked to clinical decline in patients. AIDS Res Hum Retroviruses
18:353-362, 2002.
Dunn, B.M., M.M. Goodenow, A. Gustchina, and A. Wlodawer. The family of retroviral proteases. Genome Biology 3:
reviews3006.1-3006.7, 2002. http://genomebiology.com/2002/3/4/reviews/3006.
Kou, Z.C., J.S. Puhr, M.M. Goodenow, and J.W. Sleasman. Combination antiretroviral therapy results in a rapid
increase in TCR Vß repertoire diversity within CD45RA CD8 T cells in HIV-infected children. J. Infect. Dis. 187:385397, 2003.
Kohler, J.J., D.L. Tuttle, C.R. Coberley, J.W. Sleasman, and M.M. Goodenow. Human immunodeficiency virus type 1
(HIV-1) induces the activation of multiple STATs in CD4+ T lymphocyte and monocyte/macrophage lineages. J.
Leukoc. Biol. 73:407-16, 2003.
Sleasman, J.W. and M.M. Goodenow. HIV-1 Infection. J. Allergy Clin. Immunol. 111:S582-592, 2003.
Goodenow, M.M., S.L. Rose, D.L. Tuttle, and J.W. Sleasman. HIV Fitness and Macrophages. J. Leuk. Biol. 74:65766. Epub 2003 Aug 21. 2003.
Clemente, J.C., R. Hemrajani, L.E. Blum, M.M. Goodenow, and B.M. Dunn. Secondary mutations M361 and A71V in
the human immunodeficiency virus type-1 protease can provide an advantage for the emergence of the primary
mutation D30N. Biochemistry 42:15029-35, 2003.
5
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
Tuttle, D.L., C.R. Coberley, X. Xie, Z.C. Kou, J.W. Sleasman, and M.M. Goodenow. Effects of human
immunodeficiency virus type 1 Infection on CCR5 and CXCR4 coreceptor expression on CD4 T lymphocyte subsets in
infants and adolescents. AIDS Res Hum Retrovirus. 20:305-313, 2004.
Ghaffari, G,. J. D.J. Passalacqua, M. M. Goodenow, J.W. Sleasman. Restoration of functional immunity in HIVinfected children who demonstrate high levels of viral replication and CD4 T cell reconstitution following HAART.
Pediatrics, 114:604-611, 2004.
Clemente, J.C., R.E. Moose, R. Hemrajani, LR.S. Whitford, L. Govindasamy, R. Reutzel, R. McKenna, M. AgbandjeMcKenna, M.M. Goodenow and B.M. Dunn. Comparing the accumulation of active and nonactive-site mutations in
the HIV-1 protease. Biochemistry, 43:12141-12151, 2004.
Coberley, C.R., J.J. Kohler, J.N. Brown, J.T. Oshier, H.V. Baker, M.P. Popp, J.W. Sleasman, and M.M. Goodenow.
Impact on genetic networks in human macrophages by a CCR5-strain of human immunodeficiency virus type-1 (HIV1). J. Virol. 78:11477-11486, 2004.
Chen, S., D.L. Tuttle, J.T. Oshier, H.J. Knot, W.J. Streit, M.M. Goodenow and J.K. Harrison. Transforming growth
factor-1 increases CXCR4 expression, stromal-derived factor-1 – stimulated signalling and human immunodeficiency
virus-1 entry in human monocyte-derived macrophages. Immunology, 114:565-574, 2005.
Ghaffari G., D.L. Tuttle, D.Briggs, B.R. Burkhardt, D. Bhatt, W.A. Andiman, J.W. Sleasman, and M.M. Goodenow.
Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection
of macrophages. J Virol. 79:13250-13261, 2005.
Clemente, J.C., R.M. Coman, M.M. Thiaville, L.K. Janka, J.A. Jeung, S. Nukoolkarn, L. Govindasamy, M. AgbandjeMcKenna, R. McKenna, W. Leelamanit, M.M. Goodenow, and B.M. Dunn. Analysis of HIV-1 CRF_01 A/E protease
inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir.
Biochemistry. 45:5468-5477, 2006.
Goodenow, M.M. and R.C. Collman. HIV-1 co-receptor preference is distinct from target cell tropism: a dual
parameter nomenclature to define viral phenotypes. Journal of Leukocyte Biology, 80: 965-972, 2006.
Coman, R.M., Robbins, A., Goodenow, M.M., McKenna, R., and Dunn, B.M. Expression, purification and preliminary
X-ray crystallographic studies of the human immunodeficiency virus 1 subtype C protease. Acta Crystallograph Sect.
F Struct Biol Cryst Commun. 63(Pt 4):320-3, 2007.
Salemi M, B.R. Burkhardt, R.R. Gray, G. Ghaffari, J.W. Sleasman, and M.M. Goodenow. Phylodynamics of HIV-1 in
lymphoid and non-lymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispecies.
PLoS ONE. 2:e950 1-11, 2007.
Rodriguez, C.A., S. Koch, M.M. Goodenow, and J.W. Sleasman. Clinical implications of discordant viral and immune
outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children. Immunol. Res. 40:271286, 2008.
Salemi, M., T. de Oliveira, M. Ciccozzi, G. Rezza, and M.M. Goodenow. High-resolution molecular epidemiology and
evolutionary history of HIV-1 subtypes in Albania. PLoS ONE. 3:e1390, 2008.
Coman, R.M., A.H. Robbins, M.A. Fernandez, C.T. Guilliland, A.A. Sochet, M.M. Goodenow, R. McKenna, and B.M.
Dunn. The contribution of naturally occurring polymorphisms in altering the biochemical and structural characteristics
of HIV-1 subtype C protease. Biochemistry 47:731-43, 2008.
Salemi, M. M. Ciccozzi, M.M. Goodenow, S. Montieri, D. Beshkov, I. Alexiev, I. Elenkov, T. Yakimova, T. Varleva, G.
Rezza. The HIV-1 diversity in Bulgaria: a continuous viral inflow from West and East European countries. AIDS Res.
Hum. Retrovir. 24:771-779, 2008.
Yin, L., C.A. Rodriguez, W. Hou, O. Potter, M.J. Caplan, M.M. Goodenow, and J.W. Sleasman. Antiretroviral therapy
corrects HIV-1 induced expansion of CD8+, CD45RA+, CD27-, CD11abright activated T cells. J. Allergy Clin. Immunol.
122:166-172, 2008.
Coman, R.M., A.H. Robbins, M.M. Goodenow, R. McKenna, and B.M. Dunn. High-resolution structure of unbound
human immunodeficiency virus 1 subtype C protease: implications of flap dynamics and drug resistance. Acta
Crystallogr D Biol Crystallogr. 64:754-63, 2008.
Ho S. K., R. M. Coman, J. C. Bunger, S. L. Rose, P. O'Brien, I. Munoz, B. M. Dunn, J. W. Sleasman, and M. M.
Goodenow. Drug-associated changes in amino acid residues in Gag p2, p7NC, and p6Gag/p6Pol in human
immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response. Virology.
July 1 [epub ahead of print]; 378:272-281, 2008.
6
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
Salemi M., R.R. Gray, and M.M. Goodenow. An exploratory algorithm to identify intra-host recombinant viral
sequences. Mol Phylogenet Evol, 49:618-28, 2008.
Brown, J., J. Kohler, C. Coberley, J.W. Sleasman, and M.M. Goodenow. HIV-1 activates macrophages independent
of toll-like receptors. PLoSONE, 3:e3664, 2008.
Ho, S.K., E.E. Perez, S.L. Rose, R.M. Coman, A.C. Lowe, W. Hou, C. Ma, R.M. Lawrence, B.M. Dunn, J.W.
Sleasman, and M.M. Goodenow. Genetic determinants in HIV-1 Gag and Env V3 are related to viral response to
combination antiretroviral therapy with a protease inhibitor. AIDS, 23:1631-40, 2009.
Gray, R.R, A.J. Tatem, S. Lamers, W. Hou, O. Laeyendecker, D. Serwadda, N. Sewankambo, R.H. Gray, M. Wawer,
T.C. Quinn, M.M. Goodenow, and M. Salemi. Spatial phylodynamics of HIV-1 epidemic emergence in east Africa.
AIDS 23:F9-F17, 2009.
Yin, L, Z. C. Kou, C. Rodriquez, W. Hou, M. M. Goodenow, and J. W. Sleasman. Antiretroviral therapy restores
diversity in the T cell receptor V repertoire of CD4 T cell subpopulations among HIV-Infected Children and
adolescent. Clin. Vacc. Immunol. 16:1293-1301, 2009.
Brown, J.N., M.A. Wallet, B. Krastins, D. Sarracino, and M.M. Goodenow. Proteome bioprofiles distinguish between
M1 priming and activation states in human macrophages. J. Leukoc. Biol, 87:659-666, 2010.
Wallet, M.A., S.M. Wallet, G. Guiulfo, J.W. Sleasman, and M.M. Goodenow. IFNγ primes macrophages for
inflammatory activation by high molecular weight hyaluronan. Cell. Immunol., 262:84-88, 2010.
Wallet, M.A., C.A. Rodriguez, L. Yin, , S. Saporta, S. Chinratanapisit, W. Hou, J.W. Sleasman, and M.M. Goodenow.
Microbial translocation induces persistent macrophage activation unrelated to HIV-1 levels or T cell activation following
therapy. AIDS 24:1281-90, 2010.
Gray R., M. Salemi, A. Lowe, K. Nakamura, W. Decker, M. Sinkala, C. Kankasa, C.J. Mulligan, D. Thea, L. Kuhn, G.
Aldrovandi, M.M. Goodenow. Multiple independent lineages of HIV-1 persist in breast milk and plasma. AIDS, 25:143152, 2011.
M. Salemi, M.M. Goodenow, N. Veras, M. Santoro, and C.F. Perno. Molecular epidemiology of HIV-1 CRF02_AG in
Cameroon and African patients living in Italy. AIDS Res Hum Retroviruses, 2011. [Epub ahead of print]
Strickland, S., Gray, R., Lamers, S., Burdo, T.H., Huenink, E., Nolan, D., Nowlin, B., Alvarez, X., Midkiff, C., M.M.
Goodenow, Williams, K., and Salemi, M. Significant genetic heterogeneity of the SIVmac251 viral swarm derived from
different sources. AIDS Res Hum Retroviruses, 2011. [Epub ahead of print]
Haraguichi, S., S.K. Ho, M. Morrow, M.M. Goodenow, and J.W. Sleasman. Developmental regulation of Pglycoprotein activity within thymocytes results in increased protease inhibitor activity. J. Leukoc. Biol. 2011. [Epub
ahead of print]
BOOK CHAPTERS (invited)
Goodenow, M.M., C.-K. Shih, K.G. Wiman, and W.S. Hayward. Oncogenic alterations of c-myc by avian leukosis
viruses. In Human T-Cell Leukemia-Lymphoma Viruses. R.C. Gallo, M.E. Essex and L. Gross, eds. Cold Spring
Harbor Laboratory, New York, pp. 75-84, 1984.
Wiman, K.G., C.-K. Shih, M.M. Goodenow, A.C. Hayday, H. Saito, S. Tonegawa, and W.S. Hayward. Activation of
the c-myc gene in avian and human B-cell lymphomas. In Cancer Cell 2: Oncogenes and Viral Genes, Cold Spring
Harbor Laboratory, New York, pp. 189-193, 1984.
Wain-Hobson, S., M.M. Goodenow, T. Huet, S. Kwok, and J. Sninsky. HIV viruses are rapidly evolving quasispecies.
In Retroviruses of Humans A.I.D.S. and Related Animal Diseases. M. Girard and L. Valette, eds. Pasteur Vaccins,
Paris. pp. 18-19, 1989.
Farmerie, W.G., M.M. Goodenow, and B.M. Dunn. Cloning, expression, and kinetic characterization of the feline
immunodeficiency virus proteinase. In Aspartic Proteinases: Genetics, Structures, and Mechanisms. Ben M. Dunn,
ed. Plenum Press, New York. Advances in Experimental Medicine and Biology 306:511-513, 1991.
Sleasman, J.W. and M.M. Goodenow. Pathogenesis and natural history of HIV infection. In Journal of the Florida
Medical Association, 78:678-681, 1991.
Goodenow, M.M., J.W. Sleasman, and S.L. Lamers. Persistence of multiple maternal genotypes in infants infected by
perinatal transmission. In Vaccines 93. Modern Approaches to New Vaccines including Prevention of AIDS. H.S.
7
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
Ginsberg, F. Brown, R.M. Chanock, and R.A. Lerner, eds. Cold Spring Harbor Laboratory Press, New York, 1993. pp.
125-129.
Tillman, M., F.C. Krebs, R. Hinkel, S.M. Pomeroy, M.M. Goodenow, and B. Wigdahl. Neuroglial-specific factors and
the regulation of retrovirus transcription. Adv. Neuroimmunol. 4:305-318, 1994.
Sleasman, J.W. and M.M Goodenow. HIV-1 infection: Pathogenesis and natural history. In Clinical Manual on HIV
and AIDS. J.W. Shands and D.L. Seckinger, eds. Florida Medical Association, Inc., Jacksonville. Pp. 1-6, 1995.
Krebs, F.C., M.M. Goodenow, and B. Wigdahl.
Neuroglial ATF/CREB factors interact with the human
immunodeficiency virus type 1 long terminal repeat. J. Neurovirol. 3 [Supp.1]: S28-S32, 1997.
Sleasman, J.W. and M.M. Goodenow. Human Immunodeficiency Virus and Acquired Immune Deficiency (AIDS). In
Textbook of Molecular Medicine. J.L. Jameson, ed. Humana Press, Inc. New York, NY. 1998.
Sei, S.S. and M.M. Goodenow. HIV-1 Neuropathogenesis. In Human Immunodeficiency Virus: Biology, Immunology,
and Molecular Biology. N. Saksena, ed. Medical Systems SpA, Italy. Pp. 227-266, 1998.
Sleasman, J.W., D.Tuttle, and M.M.Goodenow. HIV Infection and Acquired Immune Deficiency (AIDS): Pathogenesis
and Natural History. In Clinical Manual on HIV and AIDS. J.W.Shands and D.L.Seckinger, eds. Florida Medical
Association, Inc., Jacksonville, FL. 1999.
M.M. Goodenow, Perez, E.E., and J.W. Sleasman. Genetic variability in HIV-1 in children treated by protease
inhibitors. In Human Retroviral Infection: Immunological and Molecular Theories. H. Friedman, K. Ugen, and M.
Bendinelli, eds., Plenum Publishing Corporation, New York, NY. Pp.287-305. 2000.
M.M. Goodenow and James Kohler. HIV-1 and AIDS-related Malignancies. In Principles of Molecular Medicine.
Second Edition, M.S. Runge and C. Patterson, eds., Humana Press, Inc., Totowa, NJ. Pp 818-827. 2006.
INVITED PRESENTATIONS
International Symposium BIOTECH RIA 88. Molecular Probes: Technology and Medical Applications. Florence, Italy.
April, 1988.
IVth International Conference on AIDS. HIVs are internally highly polymorphic. Stockholm, Sweden. 1988.
Conference on Genetic Variation of Immunodeficiency Viruses. National Institute of Allergy and Infectious Diseases
AIDS
Program. Genetic Variation of HIV-1. Bethesda, MD. 1988.
Pediatric AIDS Foundation Think Tank. Genetic Variability in HIV-1 nef alleles in infected Mothers and Infants. Santa
Barbara,CA.
Southeastern Regional Developmental Biology Meeting. Expression of the Avian Proto-oncogene c-ski during
embryogenesis. Chapel Hill,North Carolina. 1991.
Center for AIDS Research, University of Alabama. Genetic Variation in Maternal-Infant Strains of HIV-1. Birmingham,
AL. 1991.
Annual Meeting on Retroviruses. HIV-1 Displays Greater Genetic Variability Over Time in Infected Infants than in their
Mothers. Cold Spring Harbor Laboratories, NY. 1992.
Fifth Annual Meeting, National Cooperative Vaccine Development Groups for AIDS. Independent Variation in env V1V2 Hypervariable Domains within Maternal-Infant Strains of HIV-1 in vivo. Chantilly, VA. 1992.
Florida Association of Biochemists and Molecular Biologists. Molecular Genetics of Human Immunodeficiency Virus
Type 1. Cocoa Beach, FL. 1993.
The Society for Pediatric Research. Multiple Maternal HIV-1 Genotypes in Infants Infected by Perinatal Transmission.
Washington, DC. 1993.
Penn State College of Medicine, Department of Microbiology and Immunology. Biological Implications of HIV-1 Genetic
Variability. The Milton S. Hershey Medical Center, Hershey, PA. 1994.
University of Massachusetts Medical School, Department of Pediatrics and the Program in Molecular Medicine. HIV-1
Genetic Variability and Maternal-Infant Transmission. Worchester, MA. 1994.
HIV-1 Early Phases Workshop. NIH, NIAID, Division of AIDS. HIV-1 Variants within PBMC Subpopulations in Infants.
Rockville, MD. 1994.
Pediatric AIDS Clinical Trial Group. Pediatric Virology Workshop. Washington, DC. 1995.
Federal University of Minas Gerais, Department of Microbiology. Genetic Variation of HIV-1 in Infected Neonates and
Children. Belo Horizonte, Brazil. 1995.
Fourth Workshop on Viral Resistance. NIH, NIAID, Division of Antiviral Drug Products and FDA, Division of Antiviral
Drug Products. HIV-infected mothers and children exhibit natural genetic variation in HIV-1 protease alleles
and in protease cleavage sites in the absence of protease inhibitors. Annapolis, MD. 1995.
8
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
1st Annual Maternal/Child HIV Care Conference. Moderator of Basic Research Session. Genetic Variation of HIV-1:
Implications for Protease Inhibitors. St. Petersburg Beach, FL. 1995.
Third International Workshop on HIV and Cells of Macrophage Lineage. Increased production of HIV-1 from
monocyte-derived macrophages by contact with endothelial and fibroblast cells. Varenna, Italy. 1996.
Twenty-third Congress of the Brazilian Society of Tropical Medicine. Early HIV-1 infection in neonates occurs in CD4
memory T l lymphocytes. Belo Horizonte, Brazil. 1997
Medical University of Minas Gerias, Department of Pediatrics and Infectious Disease. Maternal transmission of HIV-1
and the mechanisms for efficacy of zidovudine therapy in reducing perinatal infection. Belo Horizonte, Brazil.
1997.
University of South Florida College of Medicine, Department of Microbiology & Immunology. Genetic and functional
resistance in HIV-1 in response to antiviral drug therapies. Tampa, FL. 1997.
University of California, Los Angeles, Center for AIDS Research and Department of Pediatrics. Genetic variability in
protease in HIV-1 demonstrates continued viral replication in the presence of protease inhibitors.
Los
Angeles, CA. 1997.
Roche Molecular Systems. Increased sensitivity of HIV-1 detection by immunomagnetic selection of subsets of CD4
expressing peripheral blood mononuclear cells. Alameda, CA. 1997.
Yale University College of Medicine, Department of Pediatrics. Genetic variants of HIV-1 from infected mothers and
children: V3 envelope and tropism. New Haven, CT. 1997.
Lindsley F. Kimball Research Institute, New York Blood Center. Genotypic resistance to protease inhibitors in HIV-1 in
children treated with protease inhibitors. New York, NY1997.
National Cancer Institute, Division of Pediatrics. Mechanisms leading to drug resistance in HIV-1 in pediatric patients
receiving highly active antiretroviral therapy. Bethesda, MD. 1998.
International Conference on the Discovery and Clinical Development of Antiretroviral Therapies. Temporal emergence
of drug resistant HIV- occurs initially in the CD45RO subset of CD4 T cells and subsequently in CD45RA CD
lymphocytes. St. Thomas, Virgin Islands. 1998.
4th International Workshop on HIV, Cells of Macrophage Lineage, and other Reservoirs. HIV-1 with wild-type protease
persists in CD45RA CD4 T lymphocytes in the presence of drug resistant HIV-1 in the plasma. Florence, Italy.
1999.
Southern Society for Pediatric Research. Natural genetic polymorphisms in HIV-1 gag/pol impacts viral and immune
response to antiretroviral therapy with protease inhibitors in naïve patients. New Orleans, LA. 2000.
Cornell University College of Medicine. Impact of Genetic Variability in HIV-1 gag/pol on biological function:implications
for response to therapy. New York, NY. 2000.
Children’s Hospital of Philadelphia, University of Pennsylvania. Therapy response in children to protease inhibitors.
Philadelphia, PA. 2001.
University of Massachusetts Medical School, Department of Pediatrics. Mechanisms of drug-induced viral effects on
immune reconstitution. Worchester, MA 2001.
University of South Florida College of Medicine, Department of Pediatrics. St. Petersburg, FL. 2002.
University of Colorado Health Science Center, School of Medicine, Department of Pediatrics. Denver, CO. 2002.
Pediatric AIDS Clinical Trial Group. Viral fitness and antiretroviral therapies. Crystal City, VA. 2002.
Association of Academic Health Centers (AAHC) VP Research. Organizational Models: Building and Managing
collaborative research within Academic Health Centers. San Antonio, TX. 2006.
6th International Workshop for Macrophages and HIV-1. Global interactions between virus and macrophages.
Varenna, Italy. 2005.
Symposium on HIV AIDS Research. HIV-1 Genetic Diversity and Pathogenesis. Belo Horizonte, Brazil. 2006.
The Wistar Institute. The evolution of X4 from R5 viruses in vivo and positive selection in V1V2 and the effect of virus
and gp 120 on macrophages. Philadelphia, PA, 2006.
University of South Florida, College of Medicine. Research Matters: HIV-1 Genetic diversity – challenges for
controlling the prototype emerging pathogen. Tampa, FL 2006.
HIV DART 2006. HIV-1 gag polymorphisms co-vary with drug-induced protease mutations and display a dominant
effect on replicative fitness and susceptibility to protease inhibitors in subsets of CD4 lymphocytes. Cancun,
Mexico. 2006.
Stephany W. Holloway University Chair for AIDS Research. Annual Endowment Luncheon. UF. 2007.
Spring Genetics Seminar Series. Molecular genetics of HIV-1: the prototypic emerging pathogen.UF. 2007.
University of Miami Winter HIV Symposium V. Transmit, Evolve, Repeat: Constrained Developmental Evolution of X4
Viruses in Children. Miami, FL. 2008.
University of South Florida Annual Conference in Immunity and Pathogens. Transmit, Evolve, Repeat: Constrained
Evolution of HIV-1 in vivo. Tampa, FL 2008.
Introduction to Bioinformatics Techniques Applied to Molecular Epidemiology. Rome, Italy 2008.
7th International Workshop on HIV, Cells of Macrophage/Dendritic Lineage and Other Reservoirs. Colombaro di Corte
Franca, Italy, 2009.
9
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
Society for Leukocyte Biology, Cellular and Cytokine Interactions in Health and Disease, 2009. Viral pathogenesis and
interactions with toll-like receptors: HIV. Lisbon, Portugal 2009.
United States–Russia Workshop on HIV Prevention Science. Invited moderator/co-chair for Basic Science: HIV
Enzymes and Viral Replication breakout session. Moscow, Russia 2009.
NIH Workshop on Building United States-Russia Collaborative Research Teams in HIV Prevention Science. Corinthia
Hotel, St. Petersburg, Russia, 2010.
Department of Pathology, Immunology and Laboratory Medicine Research Seminar “Extensive biodiversity and
complex population structure of HIV-1 envelope 3 quasispecies within the host ecosystem”, May 19, 2010
IAS Pre-Conference Basic Science Workshop, Towards a Cure: HIV Reservoirs and Strategies to Control Them.
Invited co-chair for session “Where and what are viral reservoirs? HIV-1 Reservoirs and Sanctuary Sites.”
Vienna, Austria, July 2010.
Global Health Research Center of Central Asia, Republican AIDS Center & Almaty City AIDS Center “Molecular
Epidemiology of HIV-1”. Almaty, Republic of Kazakhstan, November 19-26, 2010.
International AIDS Vaccine Initiative [IAVI– Frontiers in AIDS Vaccine Development Seminar Series, “Vaccine
Discovery & Diversity of Human Immune Repertoire”, New York, NY, December 15, 2010.
Aaron Diamond AIDS Research Center, “HIV-1 Immune Activation & Host-Pathogen Biodiversity” New York, NY, Dec
17, 2010.
Translational Research in HIV/AIDS, “Translation of High Throughput Discovery to HIV/AIDS Persistence and
Vaccines: Systems Biology and Deep-Sequencing”, Goa, India, January 12-15, 2011.
Signature Interdisciplinary Program in Allergy, Immunology, and Infectious Disease, “New Horizons in Inflammation
and Genomics”, Tampa, Florida, May 27, 2011
CURRENT RESEARCH SUPPORT
R01 DA031017 Substance use and immunity in HIV+ infected adolescents by systems biology
PI: M.M. Goodenow, Ph.D.
NIH/NIDA
Period : 09/17/10-06/30/15
Total Award : $4.7 million
R01 AI065265 01- 05 Role of HIV-1 Env Diversity in Cellular Tropism
PI: M.M. Goodenow, Ph.D.
NIH/NIAID
Period: 04/01/05 - 03/31/10
Total Award: $2.2 million
RO1 AI28571 21-26 Human Immunodeficiency Virus Proteinase
PI: B.M. Dunn, Ph.D. NIH NIAID Merit Award
Co-PI: M.M. Goodenow, Ph.D.
NIH/NIAID
Period: 03/01/10 – 02/28/15
Total Award: $1.5 million
RO1 AI 47723 04-08 Impact of HIV-1 Genotype on Therapy Response in Children
PI: J.W. Sleasman, M.D.
Co-PI & PI of subcontract to UF: M.M. Goodenow, Ph.D.
NIH/NIAID
Period: 03/01/06 – 2/28/11
Total Award: $2.3 million
NIH P30 AG028740 Molecular mechanisms of skeletal muscle loss in HIV-infected older persons.
PI: Marco Pahor, PI
Leader, M.M. Goodenow
NIA Pepper Centers Supplement; University of Florida Older Americans Independence Center
Period: 4/10/09 – 3/31/10
Total Award: $100,000
NIH R01 NS063897-01A2 Viral evolution in peripheral macrophages and brain during progression to AIDS.
PI: Marco Salemi, PhD
Co-Investigator: M.M. Goodenow, Ph.D.
NIH/NIAID
Period: 2/15/09 – 1/31/14
Total Award: $3.5 million
10
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
R01CA098803 Natural History of HPV Infection in Men (HIM) Study
PI: A. Giuliano, Ph.D.
Co-I and PI of subcontract to University of Florida: M.M. Goodenow, Ph.D.
NIH/NCI
Period: 1/15/10-11/30/14
Total Direct Costs: $73,298
K01AA018255 Mentored Research Scientist Development Award (K01)
PI: Stephanie A.S. Stara, Ph.D.
HIV risk among racially-diverse, minority youth: Alcohol and partner selection.
Mentor: M.M. Goodenow, Ph.D.
Period: 12/1/09 – 11/30/14
Total Direct Costs: $774,899
University of Florida Foundation Stephany W. Holloway University Chair for AIDS Research
PI: M.M. Goodenow, Ph.D.
Period: 12/01/04 to present
CA09126 29-34 Training in Cell Biology and Immunobiology of Cancer
PI: W. S. May, MD, PhD
Dual PI: M.M. Goodenow, Ph.D.
Post-Doctoral Trainee: Rebecca Gray, Ph.D.
NIH/NCI
Period: 6/1/08 – 05/31/13
Total Direct Costs: $1, 547,000
NIH Training Grant in Infectious Diseases
P.I. David Bloom, Ph.D.
Co-Investigator: M.M. Goodenow, Ph.D.
NIH Training Grant in Rheumatology
PI: Wesley Reeves, M.D.
Co-Investigator: M.M. Goodenow, Ph.D.
PENDING
None
PAST SUPPORT
R21 AI078450-01 Characterization of novel polyreactive anti-HIV antibodies in autoimmunity
PI: M.M. Goodenow, Ph.D.
NIH/NIAID
Period: 04/01/2008 - 03/31/10
Total Award: $410,000
UF Cancer Center/Moffitt Collaborative Initiative In-depth assessment by pyrosequencing of prevalence of
HPV genotypes in a multi-national cohort of HPV-infected men
PI: M.M. Goodenow, Ph.D.
University of Florida Cancer Center
Period: 1/1/09 – 12/31/09
Total Award: $100,000
Development of Human Anti-HIV Antibodies as Novel Therapeutics
PI: M.M. Goodenow, Ph.D.
University of Florida Office of the VP for Research
Period: 05/01/08 – 04/30/10
Total Award: $90,000
Human Milk Antibody-Mediated Inhibition of HIV
PI: Grace Aldrovandi, MD;
Co-PI & PI of subcontract to UF: M.M. Goodenow, Ph.D.
Elizabeth Glaser Pediatric AIDS Foundation, Pediatric HIV Vaccine Program
Period: 05/01/08 – 04/30/10
Total Award: $100,000
11
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
RO1 HD32259 HIV-1 Variants within PBMC Subpopulations in Infants
M.M. Goodenow, Ph.D. 1/1/93-12/31/09 Total Award: $5.0 million
University of Florida, Division of Sponsored Research, New Faculty Research Support Program
Isolation of the Murine Homolog of a Novel Avian Retroviral Oncogene
M.M. Goodenow, P.I. 6/3/88 - 6/2/89 Total award: $5575
American Cancer Society Institutional Research Award, ACS 88-072A
Isolation of the Murine Homolog of a Novel Avian Retroviral Oncogene
M.M. Goodenow, P.I. 10/1/88 - 9/30/89
Total award: $7500
University of Florida, Interdisciplinary Center for Biotechnology Research, No.104
Biological Effects of HIV-1 Genetic Polymorphism
M.M. Goodenow, P.I.
12/1/88 - 6/30/89
Total award: $23,540
UF DSR Research Development Award: Regulation of Embryonic Oncogene Expression
M.M. Goodenow, P.I. 5/1/89 - 4/30/90 Total award: $21,050
NIH RO1 A128210. Biological Implications of HIV-1 Genetic Variability
M.M. Goodenow P.I. 12/1/89 - 11/30/94
Total Award: $913,000
Pediatric AIDS Foundation. Maternal Transmission of HIV-1 Genetic Variants
M.M. Goodenow, P.I. 10/1/89 - 9/30/91
Total award: $156,000
American Cancer Society, Florida Division Sigurd M. Johnson Research Grant
Muscle-Specific Transcripts of the Avian Proto-Oncogene c-ski
M.M. Goodenow, P.I. 1/1/91 - 12/31/91
Total award: $20,000
Children's Miracle Network Telethon Award
Memory T Cell Function in Pediatric HIV Infection
J.W. Sleasman and M.M. Goodenow, Co-P.I.s 6/1/92 - 5/30/93
Total Award: $15,000
American Foundation for AIDS Research 00167-12-RG.
Variability in HIV Proteinase and Substrates In Vivo
M.M. Goodenow, P.I. 5/1/92 - 4/30/94 Total Award: $140,000
NIH RO1 HD32259 01-08 HIV-1 Variants within PBMC Subpopulations in Infants
PI: M.M. Goodenow, Ph.D.
12/1/94 - 12/31/02
Total Award: $2,263,474
NIH RO1 AI28571 01-15 Human Immunodeficiency Virus Proteinase
PI: B.M. Dunn, Ph.D. Co-PI: M.M. Goodenow, Ph.D. 9/1/87– 5/31/05 Total Award: $4,080,496
Pediatric AIDS Foundation. In vivo Function of Pediatric HIV LTR Variants.
PI: T.P. Yang, Ph.D.; Co-PI: M.M. Goodenow, PhD
1/1/96 - 12/31/97
Total Award: $78,000
Clinical Trials of Protease Inhibitors
PI: J.W. Sleasman, M.D.
NIH R01 HL5800501-05 Activation of HIV-1 in Macrophages by Lung Cells
PI: M. M. Goodenow Period: 8/1/96 - 7/31/01 Total Award: $1,450,000
NIH RO1 AI/HD39015 01-05 Phenotype and Genotype of HIV-1 Strains from Children
PI: Warren A. Andiman, M.D., Yale University Medical School
University of Florida Contract: M. M. Goodenow, Ph.D., PI
8/1/96 to 7/31/01
Total Award: $1,600,000
NIH K08 An in vitro cell culture model for hepatitis C virus propagation
PI: R.P. Gonzalez-Peralta, M.D.; Mentors: M.M. Goodenow & B.M. Dunn
Period: 6/01/97 to 5/31/02
12
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
NIH RO1 AI 47723 Impact of HIV-1 Genotype on Therapy Response in Children
PI: M.M. Goodenow, Ph.D.
3/01/01 – 2/28/04
Total Award: $1,200,000
Pediatric AIDS Clinical Trials Group Contract
PI: M.M. Goodenow, Ph.D.
02/01/05 – 01/31/06
Total Award: $81,000
CURRENT SUPPORT FOR STUDENTS AND FELLOWS
CA09126 29-34 Training in Cell Biology and Immunobiology of Cancer
PI: W. S. May, MD, PhD
Dual PI: M.M. Goodenow, Ph.D.
Period: 6/1/08 – 05/31/13
Total Direct Costs: $1, 547,000
Fellowship for Rebecca R. Gray, Ph.D.
Laura McClamma Research Fellowship Fund
Administrator: M.M. Goodenow, Ph.D.
Support for Wilton Williams, a Ph.D. student in my laboratory.
Laura McClamma Research Fellowship Fund
Administrator: M.M. Goodenow, Ph.D.
Support for Mark A. Wallet, Ph.D. postdoctoral fellow in my laboratory.
PREVIOUS SUPPORT FOR STUDENTS AND FELLOWS
NIH Training Grant in Rheumatology
PI: Wesley Reeves, M.D.
Co-Investigator: M.M. Goodenow, Ph.D.
Postdoctoral Fellowship for Mark W. Wallet, Ph.D. 2007-2010
NIH Training Grant in Infectious Diseases
P.I. David Bloom, Ph.D.
Co-Investigator: M.M. Goodenow, Ph.D.
Support for Joshua Bunger for predoctoral training
American Association of University Women International Fellowship.
9/1/91 - 8/30/92 Total award: $13,000
Fellowship for Ms. Maria Elena Bottazzi, a predoctoral student
Southern Medical Society
7/1/92 - 6/30/93 Total award: $2500
Awarded to Thomas Otal, M.D., Ph.D., a Pathology Resident for a research rotation project in my laboratory.
American Cancer Society, Florida Division
R.G. Thompson Memorial Summer Research Fellowship
(1) 6/1/90 - 8/30/90
Total award: $2500
(2) 6/1/91 - 8/30/91
Total award: $2500
(3) 6/1/96 - 8/30/96
Total award: $2500
Division of Sponsored Research, University of Florida
Graduate Research Assistantship Support Program
(1) 1/1/90 - 8/31/90
Total award: $6475
(2) 7/1/91 - 12/31/91
Total award: $5200
Pediatric AIDS Foundation. Student Summer Intern Award
(1) 6/1/91 - 8/15/91
Total award: $2500
(2) 6/21/99 – 8/1/99
Total award: $2500
13
CURRICULUM VITAE [rev 2011 0628]
M.M.Goodenow, Ph.D.
NCI Training in Cell Biology and Immunobiology of Cancer
Total award: $270,000
Patricia Roberts Harris Fellowship, University of Florida
9/15/91 - 8/31/94
Total award: $30,000
NIH F31 GM14899 Minority Predoctoral Fellowship Program
9/15/91-3/15/97 Total award: $90,000
Support for stipend, tuition, and expenses for Elena E. Perez, an M.D./Ph.D. student in my laboratory.
Elizabeth Glaser Pediatric AIDS Foundation Scholar Award
PI: D. L. Tuttle, Ph.D.
Mentor: M.M. Goodenow, Ph.D.
Period: 3/1/98 to 2/28/00
Total Costs: $76,000
This was a mentored salary award to Dr. Tuttle, a postdoctoral fellow in my lab.
Veterans Affairs Predictors of Outcomes in HIV-Infected Males
PI: Constance R. Uphold, Ph.D.
Mentor: M.M. Goodenow
Period: 10/01/00 to 9/30/04
Total Award: $600,000
RO1 HD32259 S01-S04 HIV-1 Variants within PBMC Subpopulations in Infants
PI: M.M. Goodenow, Ph.D.
NIH/NICHD
Period: 08/01/04-12/31/08
Total Award: $0.5 million
NIH Disability Supplement for Christina Gavegnano.
14